small molecule

VELTASSA

PATIROMER SORBITEX CALCIUM

Loss of exclusivityOctober 2033latest FDA-listed patent expiry
CompanyVifor PharmaView the full company profile on CliffBio

Drug detail

Brand nameVELTASSA
Active ingredientPATIROMER SORBITEX CALCIUM
StrengthEQ 25.2GM BASE/PACKET
Dosage formPOWDER
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2015
Marketing statusDISCN

Listed patents

PatentExpiresType
9492476October 2033use U-1766
9925212October 2033use U-1766
11123363October 2033use U-1766
8337824May 2030substance
8147873June 2028product
8282913May 2027product
8216560March 2027use U-1766

Regulatory exclusivity

CodeExpires
NPPOctober 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VELTASSA patent cliff — loss of exclusivity October 2033 | CliffBio